Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

Cancer immunology research

Volumn 1, Issue 4, 2013, Pages 235-244

  Kitano, Shigehisa ^a   Tsuji, Takemasa ^a   Liu, Caillian ^a   Hirschhorn Cymerman, Daniel ^a   Kyi, Chrisann ^a   Mu, Zhenyu ^a   Allison, James P ^a   Gnjatic, Sacha ^a   Yuan, Jianda D ^a   Wolchok, Jedd D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

antibody; cytotoxic CD4+ T cell; Cytotoxic T lymphocyte antigen 4; ipilimumab; melanoma; NY ESO 1

Indexed keywords

CTAG1B PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EOMES PROTEIN, HUMAN; GRANZYME; GZMB PROTEIN, HUMAN; IPILIMUMAB; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PERFORIN; PRF1 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21; TUMOR ANTIGEN;

ADULT; ANTIGEN PRESENTING CELL; CASE REPORT; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; TUMOR CELL LINE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; FEMALE; GRANZYMES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PERFORIN; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84906939784     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0068     Document Type: Article

References (0)